High-Dose Chemotherapy and Bone Marrow Transplant for Hodgkin's Disease
Author Information
Author(s): MER O'Brien, S Milan, D Cunningham, AL Jones, M Nicolson, P Selby, T Hickish, M Hill, ME Gore, C Viner
Primary Institution: The Institute of Cancer Research and The Royal Marsden Hospital
Hypothesis
Can high-dose chemotherapy with autologous bone marrow transplantation improve outcomes in patients with relapsed Hodgkin's disease?
Conclusion
High-dose chemotherapy with autologous bone marrow transplantation can lead to a significant response rate in patients with relapsed Hodgkin's disease.
Supporting Evidence
- Of the 89 patients, 33 achieved complete remission after treatment.
- The response rate to autologous bone marrow transplantation was 74%.
- Patients who had never achieved a complete remission did not benefit from high-dose chemotherapy.
Takeaway
This study looked at 89 patients with Hodgkin's disease who received strong chemotherapy and a bone marrow transplant, and many of them got better.
Methodology
The study analyzed the outcomes of 89 patients treated with high-dose chemotherapy and autologous bone marrow transplantation, focusing on response rates and prognostic factors.
Potential Biases
Potential bias due to the retrospective nature of some data collection and the single-center design.
Limitations
The study was conducted at a single institution, which may limit the generalizability of the findings.
Participant Demographics
Median age of participants was 29 years, with a range from 15 to 51 years.
Statistical Information
P-Value
0.025
Confidence Interval
95% CI 60-83%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website